This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stephen G. Swisher, MD; E. Carmack Holmes, MD; Kelly K. Hunt, MD; Jeffrey E. Doty, MD; Michael J. Zinner, MD; David W. McFadden, MD

Arch Surg. 1996;131(8):819-825.

Abstract
Objective
To determine the effect of neoadjuvant therapy (NT) (preoperative chemotherapy, radiation therapy, or both) in surgically resectable esophageal cancer.

Design
A retrospective review over a 20-year period.

Setting
A tertiary academic medical center.

Participants
All patients undergoing surgical resection for esophageal cancer (N=316) over this time period.

Main Outcome Measures
Perioperative morbidity and mortality, local and distant recurrences, and overall survival.

Results
Patients undergoing NT (n= 106) had prognostic factors similar to those treated with surgery alone (n=210). No increase was noted in surgical morbidity with NT (anastomotic leaks, reoperation rates, complications, or extended hospital stays). Overall survival was not improved by NT (median survival, 14 months) except in the subset of patients (11/83) who responded completely (100% histological necrosis) to preoperative chemotherapy (median survival, 79.2 months; P<.02). Complete response to radiation therapy alone was not associated with improved survival. Partial necrosis of the primary tumor was seen in 13 (15%) of 83 patients but conferred no survival advantage. Complete response to preoperative chemotherapy was associated with squamous cell pathological features and excellent performance status as measured by preanesthesia evaluation.

Conclusions
The addition of NT did not increase perioperative morbidity or mortality. Only the subset of patients who had a complete response to preoperative chemotherapy showed a survival advantage. Excellent performance status and squamous cell pathological features were associated with an increased chance of complete pathological response following preoperative chemotherapy.

Arch Surg. 1996;131:819-825

Author Affiliations
From the Department of Surgery, Divisions of General Surgery (Drs Swisher, Doty, Zinner, and McFadden), Cardiothoracic Surgery (Dr Holmes), and Surgical Oncology (Dr Hunt), University of California Medical Center, Los Angeles. Drs Swisher and Hunt are currently at the University of Texas M. D. Anderson Cancer Center, Houston; Dr Zinner is currently at Brigham and Women's Hospital, Boston, Mass; and Dr Doty is currently at Good Samaritan Hospital, San Jose, Calif.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Health-related quality of life in esophageal cancer: effect of neoadjuvant chemoradiotherapy followed by surgical intervention.
Safieddine et al.
J. Thorac. Cardiovasc. Surg. 2009;137:36-42.
ABSTRACT | FULL TEXT  

Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma
Malaisrie et al.
J. Thorac. Cardiovasc. Surg. 2006;131:65-72.
ABSTRACT | FULL TEXT  

Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy
Hennessy et al.
JCO 2005;23:9304-9311.
ABSTRACT | FULL TEXT  

Impact of Induction Concurrent Chemoradiotherapy on Pulmonary Function and Postoperative Acute Respiratory Complications in Esophageal Cancer
Abou-Jawde et al.
Chest 2005;128:250-255.
ABSTRACT | FULL TEXT  

Association of GSTP1 Polymorphism and Survival for Esophageal Cancer
Lee et al.
Clin. Cancer Res. 2005;11:4749-4753.
ABSTRACT | FULL TEXT  

Effects of preoperative chemoradiotherapy on postsurgical morbidity and mortality in cT3-4 +/- cM1lymph cancer of the oesophagus and gastro-oesophageal junction
Hagry et al.
Eur. J. Cardiothorac. Surg. 2003;24:179-186.
ABSTRACT | FULL TEXT  

Pulmonary complications after esophagectomy
Avendano et al.
Ann. Thorac. Surg. 2002;73:922-926.
ABSTRACT | FULL TEXT  

Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Is It Worthwhile?
Tamim et al.
Arch Surg 1998;133:722-726.
ABSTRACT | FULL TEXT  

Is Esophagectomy Following Upfront Chemoradiotherapy Safe and Necessary?
Kane et al.
Arch Surg 1997;132:481-486.
ABSTRACT